Thrombotic thrombocytopenic purpura (TTP): Is any plasma useful to treat the TTP?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  ISBT Science Series

• Publication date

  2007-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1751-2824.2007.00069.x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura

  2007cited by this paper
• Are quality differences responsible for different adverse reactions reported for SD‐plasma from USA and Europe?

  2006cited by this paper
• Clinical practice. Thrombotic thrombocytopenic purpura.

  2006cited by this paper
• The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma

  2006cited by this paper
• Update on pathogen reduction technology for therapeutic plasma: an overview.

  2006cited by this paper
• ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma.

  2006cited by this paper
• Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome

  2006cited by this paper
• Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet

  2005cited by this paper
• Transfusion-related acute lung injury.

  2005cited by this paper
• Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature

  2005cited by this paper
• Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura

  2005cited by this paper
• Therapeutic Plasma Exchange (TPE) for Thrombotic Thrombocytopenic Purpura (TTP) Using Plasma Prepared with Photochemical Treatment (INTERCEPT Plasma).

  2004cited by this paper
• von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.

  2004cited by this paper
• Recent advances in thrombotic thrombocytopenic purpura.

  2004cited by this paper
• Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.

  2004cited by this paper
• Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.

  2004cited by this paper
• Methylene blue‐photoinactivated plasma vs. fresh‐frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura

  2004cited by this paper
• Solvent/detergent-treated plasma: composition, efficacy, and safety.

  2004cited by this paper
• Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature

  2004cited by this paper
• Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura

  2003cited by this paper
• The Canadian apheresis registry.

  2003cited by this paper
• Methylene blue‐treated fresh‐frozen plasma: what is its contribution to blood safety?

  2003cited by this paper
• Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias

  2003cited by this paper
• ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

  2003cited by this paper
• Acquired protein s deficiency in thrombotic thrombocytopenic purpura patients receiving solvent/detergent plasma exchange

  2003cited by this paper
• Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis

  2003cited by this paper
• Virus inactivation in blood components by photoactive phenothiazine dyes.

  2002cited by this paper
• Fibrinolysis During Liver Transplantation Is Enhanced by Using Solvent/Detergent Virus-Inactivated Plasma (ESDEP®)

  2002cited by this paper
• Phenothiazines and prion diseases: a potential mechanism of action towards oxidative stress.

  2002cited by this paper
• Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)

  2001cited by this paper
• Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma.

  2001cited by this paper
• A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco‐Tronic system

  2001cited by this paper
• Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura*

  2001cited by this paper
• Ten years of prophylactic treatment with fresh‐frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor‐cleaving protease

  2001cited by this paper
• Treatment of patients with factor viii autoantibodies by staphylococcal protein a‐based immunoadsorption and immunosuppression

  2001cited by this paper
• Partial amino acid sequence of purified von Willebrand factor-cleaving protease.

  2001cited by this paper
• Role of methylene blue‐treated or fresh‐frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura

  2001cited by this paper
• Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

  2001cited by this paper
• Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura‐hemolytic‐uremic syndrome

  2000cited by this paper
• von Willebrand factor‐cleaving protease activity in congenital thrombotic thrombocytopenic purpura

  2000cited by this paper
• Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent‐treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses?

  2000cited by this paper
• Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

  1998cited by this paper
• United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange

  1998cited by this paper
• SD Plasma in TTP and Coagulation Factor Deficiencies for which no Concentrates are Available

  1998cited by this paper
• von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

  1998cited by this paper
• Current status of solvent/detergent‐treated frozen plasma

  1998cited by this paper
• Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.

  1998cited by this paper
• Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.

  1996cited by this paper
• Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura

  1996cited by this paper
• Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

  1996cited by this paper
• Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange

  1995cited by this paper
• The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single‐donor fresh‐frozen plasma

  1994cited by this paper
• The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange?

  1994cited by this paper
• Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease.

  1993cited by this paper
• No evidence for neoantigens in human plasma after photochemical virus inactivation

  1992cited by this paper
• Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura

  1992cited by this paper
• Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

  1991cited by this paper
• Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

  1991cited by this paper
• [Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study].

  1991cited by this paper
• Photoinactivation of Viruses in Human Fresh Plasma by Phenothiazine Dyes in Combination with Visible Light

  1991cited by this paper
• Thrombotic microangiopathies.

  1991cited by this paper
• Treatment of thrombotic thrombocytopenic purpura

  1983cited by this paper
• Hyaline thrombosis of the terminal arterioles and capillaries : a hitherto undescribed disease

  year unknowncited by this paper

• Clinical experience in treatment of thrombotic thrombocytopenic purpura--hemolytic uremic syndrome with 28 patients.

  2013cites this paper
• Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience

  2010cites this paper